Viking Therapeutics announced the completion of patient enrollment in its Phase 2b clinical trial of VK2809, the company’s novel liver-selective thyroid hormone receptor beta agonist, in patients with biopsy-confirmed non-alcoholic steatohepatitis. The company expects to report data for the study’s primary endpoint in the first half of 2023.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- Ascletis says Viking Therapeutics complaints ‘have no merit’
- Viking sued Ascletis alleging stolen trade secrets, Reuters reports
- Biotech Alert: Searches spiking for these stocks today
- Viking Therapeutics price target raised to $15 from $10 at Maxim
